Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Dementia

Financiado

DNA rEpair impaired Mice with accElerated Neurodegeneration as Tool to Improve A...

DNA rEpair impaired Mice with accElerated Neurodegeneration as Tool to Improve Alzheimer therapeutics Alzheimer’s disease (AD) affects worldwide ~50 million people. Preclinical research relies mainly on transgenic mouse models overexpressing mutant human proteins that are altered in <5% of AD cases (e.g. β-amyloid and tau), howeve... ver más

31/12/2016

ERASMUS MC

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-PoC-2014: ERC Proof of Concept Grant

I+D

Cerrada hace 10 años

0% 100%

2 Participantes

ERASMUS MC

150.00K€ | Lider

GALA SOL

Proyectos interesantes

SAF2013-43900-R MECANISMOS TRANSCRIPCIONALES DE PERDIDA DE MEMORIA EN RATONE... 230K€ Cerrado

SAF2016-80027-R MECANISMOS TRANSCRIPCIONALES DE PLASTICIDAD SINAPTICA EN CIR... 200K€ Cerrado

CNS2023-144872 Biología integrativa y fisiología 200K€ Cerrado

SAF2010-20925 ANALISIS DEL TRANSCRIPTOMA EN RATONES TRANSGENICOS DE LA ENF... 206K€ Cerrado

PID2021-124430OA-I00 ESTUDIO DE LAS DIFERENCIAS DE SEXO EN ENFERMEDADES NEURODEGE... 157K€ Cerrado

PID2021-129053OB-I00 PLASTICIDAD DE MICROGLÍA EN DEMENCIA 169K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 19 meses Fecha Inicio: 2015-05-21
Fecha Fin: 2016-12-31

Presupuesto del proyecto 150K€

Descripción del proyecto Alzheimer’s disease (AD) affects worldwide ~50 million people. Preclinical research relies mainly on transgenic mouse models overexpressing mutant human proteins that are altered in <5% of AD cases (e.g. β-amyloid and tau), however, despite prominent protein aggregates, they fail to show the dramatic neurodegeneration and cognitive decline of patients, indicating that plaques and tangles may not be the only requirement for AD. Age is the most determining factor in AD, but is poorly represented in current AD models. Generating bona fide mouse models for various human DNA repair syndromes we have disclosed a very strong connection between DNA damage, repair and aging including dramatic neurodegeneration. Within the context of ERC-DamAge we discovered striking parallels in neurodegeneration, progressive cognitive decline and genome-wide expression profiles of repair-deficient Ercc1Δ/- mice and human AD. The similarities in expression profiles are an order of magnitude higher than current AD mouse models. We discovered that nutritional interventions can spectacularly delay neurodegeneration, opening realistic perspectives for combating AD and other neurodegenerative disorders. The primary goal of this application is to complete the characterization of the mouse mutants as a valid model for AD by a detailed quantitative comparison of all RNA classes of relevant brain compartments of Ercc1Δ/- mutants and AD patients. This not only provides the final PoC, but also an unparalleled resource for pathway analysis, target identification and biomarkers for monitoring disease progression and effects of any intervention. This application will be instrumental to facilitate transition to a valid AD model for pharmaceutical companies enabling development of effective medication for prevention and/or therapy. This proposal addresses a huge unmet medical need worldwide, which seriously affects QoL, challenges health care systems, and offers unprecedented socio-economical opportunities.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores